title: Erythropoietin does not increase the frequency of thromboembolic events or hepatocellular carcinoma in hepatitis C patients treated with combination antiviral therapy.
authors.forename: Juan F
authors.initials: JF
authors.lastname: Gallegos-Orozco
authors.forename: Kristina T
authors.initials: KT
authors.lastname: Werner
authors.forename: Marianne
authors.initials: M
authors.lastname: Rosati
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Byrne
authors.forename: Vijayan
authors.initials: V
authors.lastname: Balan
authors.forename: Hugo E
authors.initials: HE
authors.lastname: Vargas
authors.forename: Jorge
authors.initials: J
authors.lastname: Rakela
mesh_terms: D000328:Adult; D000740:Anemia / Q000139:chemically induced / Q000517:prevention & control; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D013923:Thromboembolism / Q000453:epidemiology*
chemical_list: D000998:Antiviral Agents; D004921:Erythropoietin